



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



BMS 270394

Item No. 35576

CAS Registry No.: 262433-54-5
Formal Name: 3-fluoro-4-[[[(2R)-2-hydroxy-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)acetyl]amino]-benzoic acid
MF: C₂₃H₂₆FNO₄
FW: 399.5
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BMS 270394 is supplied as a solid. A stock solution may be made by dissolving the BMS 270394 in the solvent of choice, which should be purged with an inert gas. BMS 270394 is soluble in the organic solvent DMSO at a concentration of approximately 20 mg/ml.

Description

BMS 270394 is an agonist of retinoic acid receptor γ (RAR γ ; EC₅₀ = 30 nM in a transactivation assay) and the active enantiomer of BMS 189961 (Item No. 29380).¹ It is selective for RAR γ over RAR β (EC₅₀ = 400 nM) and is inactive at RAR α . BMS 270394 synergizes with paclitaxel (Item No. 10461) to inhibit the growth of MCF-7 breast and OVCAR-3 ovarian cancer, as well as SqCC/Y1 head and neck squamous cell carcinoma, cells.²

References

1. Klaholz, B.P., Mitschler, A., Belema, M., *et al.* Enantiomer discrimination illustrated by high-resolution crystal structures of the human nuclear receptor hRAR γ . *Proc. Natl. Acad. Sci. USA* **97**(12), 6322-6327 (2000).
2. Vivat-Hannah, V., You, D., Rizzo, C., *et al.* Synergistic cytotoxicity exhibited by combination treatment of selective retinoid ligands with taxol (Paclitaxel). *Cancer Res.* **61**(24), 8703-8711 (2001).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/12/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM